NYSEAMERICAN:IGC

IGC Pharma (IGC) Stock Forecast, Price & News

$0.34

-0.02 (-5.51%)

(As of 09/25/2023 ET)

Compare

Today's Range: $0.34
▼
$0.36
50-Day Range: N/A
52-Week Range: $0.28
▼
$0.52

Volume: 133,077 shs
Average Volume: 167,464 shs
Market Capitalization: $18.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About IGC Pharma (NYSEAMERICAN:IGC) Stock

IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

IGC Price History

30 days | 90 days | 365 days | Advanced Chart

IGC Stock News Headlines

September 16, 2023 | americanbankingnews.com

IGC Pharma (NYSEAMERICAN:IGC) Stock Price Crosses Above Two Hundred Day Moving Average of $0.00

September 8, 2023 | finance.yahoo.com

IGC Pharma, Inc. (IGC)

September 26, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.

August 21, 2023 | finance.yahoo.com

IGC Announces Results of its 2023 Annual Stockholders Meeting

August 14, 2023 | finance.yahoo.com

IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials

August 9, 2023 | msn.com

IGC powers Alzheimer’s and cannabis research with AI

August 3, 2023 | benzinga.com

THC-Based Alzheimer's Trial In Puerto Rico: IGC Pharma Targets Underrepresented Hispanic Communities

August 2, 2023 | finance.yahoo.com

IGC Pharma Expands Phase 2 Trial of IGC-AD1 to Include the University of Puerto Rico

September 26, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

July 18, 2023 | finance.yahoo.com

IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference

July 12, 2023 | msn.com

IGC Pharma FY23 Revenue Grows 129%, What About Net Loss?

July 12, 2023 | finance.yahoo.com

IGC Reports Financial Results for Fiscal Year Ended March 31, 2023

July 7, 2023 | benzinga.com

IGC Pharma Secures $12M Credit Facility From O-Bank To Aid Alzheimer's Research

July 6, 2023 | msn.com

IGC Pharma Secures $3M Via Private Placement

July 6, 2023 | msn.com

IGC Raises $3M Via Private Placement With Asset Management Firm Bradbury

July 6, 2023 | finance.yahoo.com

IGC Pharma Announces a $3 Million Private Placement of its Common Stock

June 16, 2023 | fool.com

India Globalization Capital (NYSEMKT: IGC)

June 6, 2023 | finance.yahoo.com

IGC Pharma Receives Notice of Allowance for Patent on Seizures

June 5, 2023 | finance.yahoo.com

IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award

May 18, 2023 | finance.yahoo.com

IGC Pharma to Present at LD Micro Invitational XIII

May 8, 2023 | marketwatch.com

8-K: IGC Pharma, Inc.

April 19, 2023 | marketwatch.com

BioMedNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Announces Participation in Upcoming Planet MicroCap Showcase

April 18, 2023 | finance.yahoo.com

IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023

March 22, 2023 | marketwatch.com

BioMedNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) to Attend Investor Summit

March 22, 2023 | finance.yahoo.com

IGC Pharma to Attend Investor Summit

March 20, 2023 | finance.yahoo.com

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

March 5, 2023 | benzinga.com

India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer's Symptoms

See More Headlines

Receive IGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter.

IGC Company Calendar

Last Earnings: 8/10/2023
Today: 9/26/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:IGC
CUSIP: N/A
CIK: 1326205
Web: www.igcinc.us
Phone: (301) 983-0998
Fax: 240-465-0273
Employees: 61
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,510,000.00
Net Margins: -860.24%
Pretax Margin: -860.24%
Return on Equity: -64.87%
Return on Assets: -57.67%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 2.38
Quick Ratio: 1.14

Sales & Book Value

Annual Sales: $910,000.00
Price / Sales: 20.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.28 per share
Price / Book: 1.23

Miscellaneous

Outstanding Shares: 53,920,000
Free Float: 43,673,000
Market Cap: $18.49 million
Optionable: Optionable
Beta: 1.91

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Ram Mukunda (Age 64)
Pres, CEO & Director
Comp: $705k

Ms. Claudia Grimaldi (Age 52)
VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director
Comp: $245k

Mr. Rohit Goel (Age 29)
Sr. Director of Accounting & Principal Accounting Officer

Key Competitors

View All Competitors

Institutional Ownership

Renaissance Technologies LLC
Bought 52,409 shares on 8/11/2023
Ownership: 0.307%

View All Institutional Transactions

IGC Stock - Frequently Asked Questions

How have IGC shares performed in 2023?: IGC Pharma's stock was trading at $0.40 at the beginning of 2023. Since then, IGC stock has decreased by 14.3% and is now trading at $0.3430.
View the best growth stocks for 2023 here.
Are investors shorting IGC Pharma?: IGC Pharma saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 850,600 shares, an increase of 7.0% from the August 15th total of 795,000 shares. Based on an average daily trading volume, of 207,200 shares, the days-to-cover ratio is presently 4.1 days. Approximately 2.1% of the company's shares are short sold.
View IGC Pharma's Short Interest.
How were IGC Pharma's earnings last quarter?: IGC Pharma, Inc. (NYSEAMERICAN:IGC) issued its quarterly earnings results on Thursday, August, 10th. The construction company reported ($0.04) EPS for the quarter. The construction company had revenue of $0.56 million for the quarter. IGC Pharma had a negative net margin of 860.24% and a negative trailing twelve-month return on equity of 64.87%.
What other stocks do shareholders of IGC Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO).

What is IGC Pharma's stock symbol?: IGC Pharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IGC."
Who are IGC Pharma's major shareholders?: IGC Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.31%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Ram Mukunda and Richard K Prins.
View institutional ownership trends.
How do I buy shares of IGC Pharma?: Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IGC Pharma's stock price today?: One share of IGC stock can currently be purchased for approximately $0.34.
How much money does IGC Pharma make?: IGC Pharma (NYSEAMERICAN:IGC) has a market capitalization of $18.49 million and generates $910,000.00 in revenue each year. The construction company earns $-11,510,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.
How can I contact IGC Pharma?: IGC Pharma's mailing address is 4336 Montgomery Ave, BETHESDA, MD 20814-4443, United States. The official website for the company is www.igcinc.us. The construction company can be reached via phone at (301) 983-0998, via email at info@igcinc.us, or via fax at 240-465-0273.

This page (NYSEAMERICAN:IGC) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial